The tweet was deleted by the author.
But we saved everything 🙂.
Nuvalent is set to present significant data at the 2025 IASLC ASCO North America Lung Cancer Conference. This presentation will mark the first public disclosure of patient-reported outcomes from the Phase 2 portion of their ARROS-1 Phase 1/2 clinical trial involving zidesamtinib, an investigational candidate.
The disclosure is expected to provide valuable insights into the efficacy and safety profiles of zidesamtinib, contributing to the broader understanding of its potential as a treatment option. This event is a key moment for Nuvalent as it seeks further validation for its candidate in the competitive field of cancer treatment.